齐默生物报告第三季度净销售额增长4.0%,达到1824亿美元,面临ERP挑战并修订2024年全年预测. Zimmer Biomet reports 4.0% rise in Q3 net sales to $1.824bn, facing ERP challenges and revising full-year 2024 guidance.
Zimmer Biomet报告说,第三季度净销售额增加了4.0%,共计18.24亿美元,每股收益减少1.23美元。 Zimmer Biomet reported a 4.0% rise in third-quarter net sales, totaling $1.824 billion, with diluted earnings of $1.23 per share. 调整后的每股收入为1.74美元,达到了分析师的预期。 Adjusted earnings per share were $1.74, meeting analyst expectations. 该公司面临企业资源规划实施方面的挑战,并修订了其2024年全年指南,降低了预计收入增长,并调整了EPS。 The company faces ERP implementation challenges and has revised its full-year 2024 guidance, lowering projected revenue growth and adjusted EPS. 它计划在2024年AAHKS会议和最近获得的OrthoGrid Systems Inc会议上启动Z1TMFemoral Hip系统。 It plans to launch the Z1™ Femoral Hip System at the 2024 AAHKS meeting and recently acquired OrthoGrid Systems Inc.